Article

Acambis and Bavarian Settle Disputes

Acambis (Cambridge, UK, www.acambis.com) and Bavarian Nordic (Kvistg?rd, Denmark, www.bavarian-nordic.com) have reached a global settlement ending the legal disputes between the two companies on matters relating to smallpox vaccines based on the modified vaccinia ankara (MVA) virus.

Acambis (Cambridge, UK, www.acambis.com) and Bavarian Nordic (Kvistgård, Denmark, www.bavarian-nordic.com) have reached a global settlement ending the legal disputes between the two companies on matters relating to smallpox vaccines based on the modified vaccinia ankara (MVA) virus. Under the agreement, Bavarian Nordic will grant a license to some of its MVA patents in return for making an undisclosed upfront payment from Acambis.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.